Opportunities Preloader

Please Wait.....

Report

U.S. Digital Therapeutics Market - Industry Outlook and Forecast 2022-2027

Market Report I 2022-06-20 I 188 Pages I Arizton Advisory & Intelligence

The Digital Therapeutics market in the U.S. is expected to grow at a CAGR of 33.15% during 2022-2027

The following factors are likely to contribute to the growth of the U.S. digital therapeutics market:

- Rise in Chronic Diseases and Need for Controlling Healthcare Costs
- Increase in Adoption of Healthcare Applications & Smart Wearables
- Rising Importance of A.I. in Digital Therapeutics
- Growing demand for Virtual Reality in DTx

MARKET OVERVIEW

Healthcare and technology have merged and created a new category of digital health known as digital therapeutics. It is a subset of digital health and a form of digital medicine that can maximize patient care and healthcare outcomes through independent use or in conjunction with pharmaceuticals. Examples of digital therapeutics include- wearable devices, digital sensors, and artificial intelligence-powered devices.

Digital therapeutics plays a significant role in the treatment and disease management of various chronic and mental health conditions. It presents potential solutions for chronic disease management, ranging from congestive heart failure, type 2 diabetes, Alzheimer's disease, and cancer. Common and expensive chronic conditions include diabetes, obesity, hypertension, heart disease, Alzheimer's disease, depression, arthritis, anxiety, and sleep disorders.

Digital therapeutics (DTx) deliver evidence-based therapeutic interventions to patients driven by high-quality software programs to prevent, manage, or treat a medical disorder or disease. They are used independently or in concert with medications, devices, or other therapies to optimize patient care and health outcomes. DTx products incorporate advanced technology best practices relating to design, clinical validation, usability, and data security. Regulatory bodies must validate them to support product claims about risk, efficacy, and intended use. It empowers patients, healthcare providers, and payers with intelligent and accessible tools for addressing a wide range of conditions through high-quality, safe, and effective data-driven interventions.

Regulatory jurisdictions most frequently categorize digital therapeutics as a subset of software as a Medical Device (SaMD), a framework developed by the International Medical Device Regulators Forum (IMDRF). All DTx products qualify as SaMD, but not all SaMD products are approved as digital therapeutic. However, a dedicated FDA regulatory framework for SaMD products remains in flux. Some DTx must undergo randomized controlled trials under the premarket approval process to demonstrate safety and efficacy like traditional pharmaceuticals.

Entry of Several Start-ups and Rapid Surge in Funding & Investments for DTx Companies

The goal of digital therapeutics is to treat chronic conditions at scale, relieving some of the significant stressors on the medical system, such as physician shortages. With the rise in the prevalence of chronic diseases, there has been a growing awareness of digital therapeutics. Owing to the gradual adoption of DTx, several companies have emerged in digital therapeutics, working with extreme expertise and intent to satisfy therapeutic needs. Furthermore, digital therapeutics saw significant funding growth in 2021, with start-ups delivering medical interventions using evidence-based software for managing and treating a broad spectrum of diseases reporting surging investments. Investments in DTx were at a record in 2020 with $1,065 million with 64 deals. DTx start-ups are likely to increase at an incredible rate, and competition is fierce for the favor of providers, payors, and employers.

Digital therapeutic solutions have caught the eye of big pharmaceutical organizations that started to invest and form strategic alliances with digital therapeutic companies. The rising need to create value beyond drug discoveries, increasing pricing pressures, and the steady incline in chronic and complex diseases all around the globe have majorly contributed to these partnerships. For instance, in early 2021, Click Therapeutics and Otsuka Pharmaceuticals announced a new remote clinical trial conducted on Verily's Project Baseline platform. In addition to this, many DTx companies have attracted significant venture and private equity financing to compete with traditional biotech pharma & companies developing drugs for similar indications. For instance, Pear Therapeutics developing DTx for substance and opioid use disorder raised around $139 million.

Digital therapeutics and telehealth companies can contribute to solutions more effectively than ever by leveraging data available from wearables and other digital sources. These technologies can drive more profound insight, influencing patient behaviors to prevent and manage chronic conditions. With the pandemic significantly raising the adoption of telehealth and virtual care, telehealth companies are looking up to digital therapeutic platforms to enhance the value of their services. For example, Aetna's telehealth business unit, Healthagen, collaborated with Welldoc and LifeScan to assess the usage and potential health benefits of OneTouch Reveal Plus.

Artificial Intelligence & Virtual Reality assisted Digital Therapeutics.

Software applications are playing a significant role in providing digital therapeutic solutions. Mobile app-based digital therapeutic programs are being delivered at a low cost and massive scale, helping prevent disease progression and potentially saving insurers billions of dollars. Some digital therapeutics are entirely replacing medication with behavioral-based treatment, such as apps that use visualization exercises to help people with insomnia.

For the DTx industry specifically, where many new and innovative applications are launched frequently, A.I. plays a major role in driving personalization and engagement to help patients achieve better health. AI-enabled therapeutics offer diagnosis and personalized care by tailoring the treatment itself and anticipating needs and challenges based on the individual's behavior. Digital therapeutics coupled with artificial intelligence (A.I.) and machine learning (ML) allows more effective clinical observations and management at the population level for various health conditions. Furthermore, virtual reality in digital therapeutics is gaining significant attention. It focuses on mental health, such as studying the mental states based on brainwave patterns. It also targets the promotion of healthy lifestyles through innovative virtual coaching.

Impact of COVID-19 on Digital Therapeutics

After the COVID-19 pandemic broke out, the utilization of DTx applications in various fields boomed. DTx provides unique solutions to satisfy healthcare needs, reducing the danger of COVID-19 exposure during a hospital visit. The COVID-19 pandemic joined the other major drivers for the growth of DTx, such as enhanced focus on preventive healthcare, high incidence of chronic diseases, and affordable gadgets due to technological advancements. In the post COVID era, DTx became a dominant player in the digital health industry, and its scope is likely to rise.

Insights by application

In 2021, the treatment & disease management segment accounted for the largest share of more than 80%. This treatment & management market will increase its domination during the forecast period and is likely to grow at a faster growth. This segment includes managing and treating diseases like chronic care, mental health & neurological disorders by using DTx. Digital therapeutics are being increasingly adopted due to the growing concern of chronic diseases. It is intended to help patients change their behaviors, often through cognitive-behavioral therapy (CBT), to successfully implement care plans for their chronic health or mental health conditions.

- Treatment & Disease Management: Vendors targeting the treatment and management of various diseases are Teladoc, Canary Health, Noom, Cognoa, Pear Therapeutics, CureApp, 2Morrow, Sharecare, and others
- Preventive Care: This includes pre-diabetes, weight management, and others. Vendors involved in providing digital therapeutics in these areas are Omada Health, One drop, WellDoc, Lark Health, and others.

Insights by End-users

In 2021, healthcare providers accounted for the largest share of 29.11% in the digital therapeutics market in the U.S. Digital therapeutics empower patients, healthcare providers, and payers with intelligent and accessible tools for addressing a wide range of conditions through high quality, safe, and effective data-driven interventions. It promises many advantages for physicians, care providers, patients, payers, employers, and other stakeholders. As primary end-users, patients are at the core of the DTx landscape. Most therapies are delivered via smartphones or tablets to patients, increasing access to care compared to traditional treatments.

Segmentation by Application
- Treatment & Disease Management
o Chronic Care
o Mental Health & Neurological Disorders
o Others
- Preventive Care
o Pre-Diabetes
o Weight Management
o Others

Segmentation by End-User
- Healthcare Providers
- Patients/Individuals
- Payers
- Employers
- Others

COMPETITIVE SCENARIO
Vendors dominating the digital therapeutics market are developing strategies such as partnerships, collaborations, joint ventures, mergers, and acquisitions for their growth and establishment. Major companies made successful partnerships to advance the adoption of DTx. Noom and Eversana partnered up to cater to patients with chronic conditions and rare diseases and check patient adherence and engagement for long-drawn-out therapies. The consolidation in the digital therapeutics market continues with vendors indulging in strategic acquisitions and collaborations with pharmaceutical companies to enter the digital therapeutics space and extend their presence in the market. Some significant acquisitions also took place in the DTx market. These include Biofourmis acquiring Gaido Health, Virgin Pulse acquiring Blue Mesa, and Novartis acquiring the digital therapeutics firm, Amblyotech. Over the next five years, there will likely be an uptick in mergers and acquisitions and closures among DTx companies.

Key Vendors
- 2Morrow
- Akili Interactive Labs
- Cognoa
- Fitbit
- Kaia Health
- Lark Technologies
- Teladoc Health
- Omada Health
- Pear Therapeutics
- ResMed
- Voluntis
- WellDoc
- Dario Health
- Happify Health
- One Drop
- Virta Health

Other Prominent Vendors
- Ayogo
- BehaVR
- Calibrate Health
- Canary Health
- Cara Care
- CardioRenal
- Cerebral
- CogniFit
- CureApp
- Freespira
- Ginger
- Glooko
- Kelvi
- Mahana Therapeutics
- Mantra Health
- Meru Health
- Monument
- Neurotrack Technologies
- NightWare
- Noom
- Sharecare
- SWORD Health
- Talkspace
- Thirty Madison
- TRIPP
- Vida Health
- Vivante Health
- Workit Health

KEY QUESTIONS ANSWERED
1. HOW BIG IS THE U.S. DIGITAL THERAPEUTICS MARKET?
2. WHAT IS THE GROWTH RATE OF THE DIGITAL THERAPEUTICS MARKET IN THE UNITED STATES?
3. WHAT ARE THE KEY COMPANIES IN THE DIGITAL THERAPEUTICS MARKET IN U.S.?
4. WHAT ARE THE MAJOR DRIVERS IN THE US DIGITAL THERAPEUTICS MARKET?
5. WHAT ARE THE LATEST TRENDS & OPPORTUNITIES IN THE US DIGITAL THERAPEUTICS MARKET?

1 RESEARCH METHODOLOGY
2 RESEARCH OBJECTIVES
3 RESEARCH PROCESS

4 SCOPE & COVERAGE
4.1 MARKET DEFINITION
4.1.1 INCLUSIONS
4.1.2 EXCLUSIONS
4.1.3 MARKET ESTIMATION CAVEATS
4.2 BASE YEAR
4.3 SCOPE OF THE STUDY
4.3.1 MARKET SEGMENTATION BY APPLICATION
4.3.2 MARKET SEGMENTATION BY END-USER

5 REPORT ASSUMPTIONS & CAVEATS
5.1 KEY CAVEATS
5.2 CURRENCY CONVERSION
5.3 MARKET DERIVATION

6 MARKET AT A GLANCE
7 INTRODUCTION
7.1 OVERVIEW
7.1.1 STEPS TO INTEGRATE DIGITAL THERAPEUTICS
7.1.2 CORE PRINCIPLES FOR DIGITAL THERAPEUTIC PRODUCTS
7.1.3 DIGITAL THERAPEUTIC PRODUCT CATEGORIES
7.1.4 SOME MAJOR MILESTONES IN DTX HISTORY
7.2 SOFTWARE AS A MEDICAL DEVICE (SAMD)
7.3 REGULATORY SCENARIO
7.4 REIMBURSEMENT SCENARIO
7.5 MAJOR FDA APPROVED DIGITAL THERAPEUTICS
7.6 IMPACT OF COVID-19 ON DIGITAL THERAPEUTICS

8 MARKET OPPORTUNITIES & TRENDS
8.1 MARKET ENTRY OF NUMEROUS DTX START-UPS
8.2 STRATEGIC COLLABORATIONS BETWEEN DTX VENDORS AND PHARMA & MEDICAL DEVICE COMPANIES
8.3 RAPID SURGE IN FUNDING & INVESTMENTS IN DIGITAL THERAPEUTICS
8.4 PROMISING PIPELINE OF DIGITAL THERAPEUTIC SOLUTIONS
8.5 TELEHEALTH PLAYERS LEVERAGING DTX PLATFORMS TO EXPAND CAPABILITIES

9 MARKET GROWTH ENABLERS
9.1 RISE IN CHRONIC DISEASES & NEED FOR CONTROLLING HEALTHCARE COSTS
9.2 INCREASED ADOPTION OF HEALTHCARE APPLICATIONS & SMART WEARABLES
9.3 ACQUISITIONS & COLLABORATIONS IN DIGITAL THERAPEUTICS
9.4 RISING IMPORTANCE OF AI IN DIGITAL THERAPEUTICS
9.5 GROWING DEMAND FOR VIRTUAL REALITY IN DTX

10 MARKET GROWTH RESTRAINTS
10.1 GROWING CONCERNS ABOUT PATIENT DATA PRIVACY
10.2 ECONOMICAL & TECHNICAL CHALLENGES INVOLVED WITH DTX
10.3 CHALLENGES WITH CLINICAL VALIDATION & STRINGENT REGULATORY GUIDELINES

11 MARKET LANDSCAPE
11.1 MARKET OVERVIEW
11.2 MARKET SIZE & FORECAST
11.2.1 INSIGHTS BY APPLICATION
11.2.2 INSIGHTS BY TREATMENT & DISEASE MANAGEMENT
11.2.3 INSIGHTS BY PREVENTIVE CARE
11.2.4 INSIGHTS BY END-USERS
11.3 FIVE FORCES ANALYSIS
11.3.1 THREAT OF NEW ENTRANTS
11.3.2 BARGAINING POWER OF SUPPLIERS
11.3.3 BARGAINING POWER OF BUYERS
11.3.4 THREAT OF SUBSTITUTES
11.3.5 COMPETITIVE RIVALRY

12 APPLICATION
12.1 MARKET SNAPSHOT & GROWTH ENGINE
12.2 MARKET OVERVIEW

13 TREATMENT & DISEASE MANAGEMENT
13.1 MARKET OVERVIEW
13.2 MARKET SIZE & FORECAST
13.3 CHRONIC CARE
13.3.1 MARKET OVERVIEW
13.3.2 MARKET SIZE & FORECAST
13.4 MENTAL HEALTH & NEUROLOGICAL DISORDERS
13.4.1 MARKET OVERVIEW
13.4.2 MARKET SIZE & FORECAST
13.5 OTHERS
13.5.1 MARKET OVERVIEW
13.5.2 MARKET SIZE & FORECAST

14 PREVENTIVE CARE
14.1 MARKET OVERVIEW
14.2 MARKET SIZE & FORECAST
14.3 PRE-DIABETES
14.3.1 MARKET OVERVIEW
14.3.2 MARKET SIZE & FORECAST
14.4 WEIGHT MANAGEMENT
14.4.1 MARKET OVERVIEW
14.4.2 MARKET SIZE & FORECAST
14.5 OTHERS
14.5.1 MARKET OVERVIEW
14.5.2 MARKET SIZE & FORECAST

15 END-USER
15.1 MARKET SNAPSHOT & GROWTH ENGINE
15.2 MARKET OVERVIEW
15.3 HEALTHCARE PROVIDERS
15.3.1 MARKET OVERVIEW
15.3.2 MARKET SIZE & FORECAST
15.4 PATIENTS/ INDIVIDUALS
15.4.1 MARKET OVERVIEW
15.4.2 MARKET SIZE & FORECAST
15.5 PAYERS
15.5.1 MARKET OVERVIEW
15.5.2 MARKET SIZE & FORECAST
15.6 EMPLOYERS
15.6.1 MARKET OVERVIEW
15.6.2 MARKET SIZE & FORECAST
15.7 OTHERS
15.7.1 MARKET OVERVIEW
15.7.2 MARKET SIZE & FORECAST

16 COMPETITIVE LANDSCAPE
16.1 COMPETITION OVERVIEW
16.2 MARKET SHARE ANALYSIS

17 KEY COMPANY PROFILES
17.1 2MORROW
17.1.1 BUSINESS OVERVIEW
17.1.2 PRODUCT OFFERINGS
17.1.3 KEY STRATEGIES
17.1.4 KEY STRENGTHS
17.1.5 KEY OPPORTUNITIES
17.2 AKILI INTERACTIVE LABS
17.2.1 BUSINESS OVERVIEW
17.2.2 PRODUCT OFFERINGS
17.2.3 KEY STRATEGIES
17.2.4 KEY STRENGTHS
17.2.5 KEY OPPORTUNITIES
17.3 COGNOA
17.3.1 BUSINESS OVERVIEW
17.3.2 PRODUCT OFFERINGS
17.3.3 KEY STRATEGIES
17.3.4 KEY STRENGTHS
17.3.5 KEY OPPORTUNITIES
17.4 FITBIT
17.4.1 BUSINESS OVERVIEW
17.4.2 PRODUCT OFFERINGS
17.4.3 KEY STRATEGIES
17.4.4 KEY STRENGTHS
17.4.5 KEY OPPORTUNITIES
17.5 KAIA HEALTH
17.5.1 BUSINESS OVERVIEW
17.5.2 PRODUCT OFFERINGS
17.5.3 KEY STRATEGIES
17.5.4 KEY STRENGTHS
17.5.5 KEY OPPORTUNITIES
17.6 LARK TECHNOLOGIES
17.6.1 BUSINESS OVERVIEW
17.6.2 PRODUCT OFFERINGS
17.6.3 KEY STRATEGIES
17.6.4 KEY STRENGTHS
17.6.5 KEY OPPORTUNITIES
17.7 TELADOC HEALTH
17.7.1 BUSINESS OVERVIEW
17.7.2 PRODUCT OFFERINGS
17.7.3 KEY STRATEGIES
17.7.4 KEY STRENGTHS
17.7.5 KEY OPPORTUNITIES
17.8 OMADA HEALTH
17.8.1 BUSINESS OVERVIEW
17.8.2 PRODUCT OFFERINGS
17.8.3 KEY STRATEGIES
17.8.4 KEY STRENGTHS
17.8.5 KEY OPPORTUNITIES
17.9 PEAR THERAPEUTICS
17.9.1 BUSINESS OVERVIEW
17.9.2 PRODUCT OFFERINGS
17.9.3 KEY STRATEGIES
17.9.4 KEY STRENGTHS
17.9.5 KEY OPPORTUNITIES
17.10 RESMED
17.10.1 BUSINESS OVERVIEW
17.10.2 PRODUCT OFFERINGS
17.10.3 KEY STRATEGIES
17.10.4 KEY STRENGTHS
17.10.5 KEY OPPORTUNITIES
17.11 VOLUNTIS
17.11.1 BUSINESS OVERVIEW
17.11.2 PRODUCT OFFERINGS
17.11.3 KEY STRATEGIES
17.11.4 KEY STRENGTHS
17.11.5 KEY OPPORTUNITIES
17.12 WELLDOC
17.12.1 BUSINESS OVERVIEW
17.12.2 PRODUCT OFFERINGS
17.12.3 KEY STRATEGIES
17.12.4 KEY STRENGTHS
17.12.5 KEY OPPORTUNITIES
17.13 DARIO HEALTH
17.13.1 BUSINESS OVERVIEW
17.13.2 PRODUCT OFFERINGS
17.13.3 KEY STRATEGIES
17.13.4 KEY STRENGTHS
17.13.5 KEY OPPORTUNITIES
17.14 HAPPIFY HEALTH
17.14.1 BUSINESS OVERVIEW
17.14.2 PRODUCT OFFERINGS
17.14.3 KEY STRATEGIES
17.14.4 KEY STRENGTHS
17.14.5 KEY OPPORTUNITIES
17.15 ONE DROP
17.15.1 BUSINESS OVERVIEW
17.15.2 PRODUCT OFFERINGS
17.15.3 KEY STRATEGIES
17.15.4 KEY STRENGTHS
17.15.5 KEY OPPORTUNITIES
17.16 VIRTA HEALTH
17.16.1 BUSINESS OVERVIEW
17.16.2 PRODUCT OFFERINGS
17.16.3 KEY STRATEGIES
17.16.4 KEY STRENGTHS
17.16.5 KEY OPPORTUNITIES

18 OTHER PROMINENT VENDORS
18.1 AYOGO
18.1.1 BUSINESS OVERVIEW
18.1.2 PRODUCT OFFERINGS
18.2 BEHAVR
18.2.1 BUSINESS OVERVIEW
18.2.2 PRODUCT OFFERINGS
18.3 CALIBRATE HEALTH
18.3.1 BUSINESS OVERVIEW
18.3.2 PRODUCT OFFERINGS
18.4 CANARY HEALTH
18.4.1 BUSINESS OVERVIEW
18.4.2 PRODUCT OFFERINGS
18.5 CARA CARE
18.5.1 BUSINESS OVERVIEW
18.5.2 PRODUCT OFFERINGS
18.6 CARDIORENAL
18.6.1 BUSINESS OVERVIEW
18.6.2 PRODUCT OFFERINGS
18.7 CEREBRAL
18.7.1 BUSINESS OVERVIEW
18.7.2 PRODUCT OFFERINGS
18.8 COGNIFIT
18.8.1 BUSINESS OVERVIEW
18.8.2 PRODUCT OFFERINGS
18.9 CUREAPP
18.9.1 BUSINESS OVERVIEW
18.9.2 PRODUCT OFFERINGS
18.10 FREESPIRA
18.10.1 BUSINESS OVERVIEW
18.10.2 PRODUCT OFFERINGS
18.11 GINGER
18.11.1 BUSINESS OVERVIEW
18.11.2 PRODUCT OFFERINGS
18.12 GLOOKO
18.12.1 BUSINESS OVERVIEW
18.12.2 PRODUCT OFFERINGS
18.13 KELVI
18.13.1 BUSINESS OVERVIEW
18.13.2 PRODUCT OFFERINGS
18.14 MAHANA THERAPEUTICS
18.14.1 BUSINESS OVERVIEW
18.14.2 PRODUCT OFFERINGS
18.15 MANTRA HEALTH
18.15.1 BUSINESS OVERVIEW
18.15.2 PRODUCT OFFERINGS
18.16 MERU HEALTH
18.16.1 BUSINESS OVERVIEW
18.16.2 PRODUCT OFFERINGS
18.17 METAME HEALTH
18.17.1 BUSINESS OVERVIEW
18.17.2 PRODUCT OFFERINGS
18.18 MONUMENT
18.18.1 BUSINESS OVERVIEW
18.18.2 PRODUCT OFFERINGS
18.19 NEUROTRACK TECHNOLOGIES
18.19.1 BUSINESS OVERVIEW
18.19.2 PRODUCT OFFERINGS
18.20 NIGHTWARE
18.20.1 BUSINESS OVERVIEW
18.20.2 PRODUCT OFFERINGS
18.21 NOOM
18.21.1 BUSINESS OVERVIEW
18.21.2 PRODUCT OFFERINGS
18.22 SHARECARE
18.22.1 BUSINESS OVERVIEW
18.22.2 PRODUCT OFFERINGS
18.23 SWORD HEALTH
18.23.1 BUSINESS OVERVIEW
18.23.2 PRODUCT OFFERINGS
18.24 TALKSPACE
18.24.1 BUSINESS OVERVIEW
18.24.2 PRODUCT OFFERINGS
18.25 THIRTY MADISON
18.25.1 BUSINESS OVERVIEW
18.25.2 PRODUCT OFFERINGS
18.26 TRIPP
18.26.1 BUSINESS OVERVIEW
18.26.2 PRODUCT OFFERINGS
18.27 VIDA HEALTH
18.27.1 BUSINESS OVERVIEW
18.27.2 PRODUCT OFFERINGS
18.28 VIVANTE HEALTH
18.28.1 BUSINESS OVERVIEW
18.28.2 PRODUCT OFFERINGS
18.29 WORKIT HEALTH
18.29.1 BUSINESS OVERVIEW
18.29.2 PRODUCT OFFERINGS

19 REPORT SUMMARY
19.1 KEY TAKEAWAYS
19.2 STRATEGIC RECOMMENDATIONS

20 QUANTITATIVE SUMMARY
20.1 MARKET BY APPLICATION
20.2 MARKET BY TREATMENT & DISEASE MANAGEMENT
20.3 MARKET BY PREVENTIVE CARE
20.4 MARKET BY END-USER

21 APPENDIX
21.1 ABBREVIATIONS

LIST OF EXHIBITS

EXHIBIT 1 SEGMENTATION OF THE US DIGITAL THERAPEUTICS MARKET
EXHIBIT 2 MARKET SIZE CALCULATION APPROACH 2021
EXHIBIT 3 PATH TO LAUNCHING DIGITAL THERAPEUTICS
EXHIBIT 4 PRODUCT CATEGORIES OF DIGITAL THERAPEUTICS
EXHIBIT 5 WORKFLOW OF A SOFTWARE AS A MEDICAL DEVICE (SAMD)
EXHIBIT 6 US FDA REGULATORY FRAMEWORK FOR DIGITAL THERAPEUTICS
EXHIBIT 7 IMPACT OF MARKET ENTRY OF NUMEROUS DTX START-UPS
EXHIBIT 8 MAJOR DIGITAL THERAPEUTIC START-UP COMPANIES IN US
EXHIBIT 9 IMPACT OF STRATEGIC COLLABORATIONS BETWEEN DTX VENDORS AND PHARMA & MEDICAL DEVICE COMPANIES
EXHIBIT 10 DIGITAL THERAPEUTICS & PHARMA DEALS BY THERAPEUTIC AREA
EXHIBIT 11 IMPACT OF RAPID SURGE IN FUNDING & INVESTMENTS IN DIGITAL THERAPEUTICS
EXHIBIT 12 DIGITAL HEALTH FUNDING IN US 2010-2020 ($ BILLION)
EXHIBIT 13 NUMBER OF DEALS IN DIGITAL HEALTH 2011-2021
EXHIBIT 14 IMPACT OF PROMISING PIPELINE OF DIGITAL THERAPEUTIC SOLUTIONS
EXHIBIT 15 LIST OF DIGITAL THERAPEUTICS PIPELINE BY STAGE OF DEVELOPMENT FOR SELECT VENDORS
EXHIBIT 16 COMPARISON OF INTERVENTIONAL DIGITAL THERAPEUTICS CLINICAL TRIALS BY INDUSTRY & ACADEMIC INSTITUTES 2014-2019
EXHIBIT 17 IMPACT OF TELEHEALTH PLAYERS LEVERAGING DTX PLATFORMS TO EXPAND CAPABILITIES
EXHIBIT 18 IMPACT OF RISE IN CHRONIC DISEASES & NEED FOR CONTROLLING HEALTHCARE COSTS
EXHIBIT 19 IMPACT OF INCREASED ADOPTION OF HEALTHCARE APPLICATIONS & SMART WEARABLES
EXHIBIT 20 IMPACT OF ACQUISITIONS & COLLABORATIONS IN DIGITAL THERAPEUTICS
EXHIBIT 21 IMPACT OF RISING IMPORTANCE OF AI IN DIGITAL THERAPEUTICS
EXHIBIT 22 IMPACT OF GROWING DEMAND FOR VIRTUAL REALITY IN DTX
EXHIBIT 23 IMPACT OF GROWING CONCERNS ABOUT PATIENT DATA PRIVACY
EXHIBIT 24 IMPACT OF ECONOMICAL & TECHNICAL CHALLENGES INVOLVED WITH DTX
EXHIBIT 25 IMPACT OF CHALLENGES WITH CLINICAL VALIDATION & STRINGENT REGULATORY GUIDELINES
EXHIBIT 26 US DIGITAL THERAPEUTICS MARKET 2021-2027 ($ MILLION)
EXHIBIT 27 US DIGITAL THERAPEUTICS MARKET BY APPLICATION
EXHIBIT 28 US DIGITAL THERAPEUTICS MARKET BY TREATMENT & DISEASE MANAGEMENT
EXHIBIT 29 US DIGITAL THERAPEUTICS MARKET BY PREVENTIVE CARE
EXHIBIT 30 US DIGITAL THERAPEUTICS MARKET BY END-USER
EXHIBIT 31 FIVE FORCES ANALYSIS 2021
EXHIBIT 32 INCREMENTAL GROWTH BY APPLICATION 2021 & 2027
EXHIBIT 33 ANNUAL INCREMENT COST PER PERSON IN US FOR VARIOUS CONDITIONS
EXHIBIT 34 US DIGITAL THERAPEUTICS MARKET BY APPLICATION: INCREMENTAL GROWTH
EXHIBIT 35 US DIGITAL THERAPEUTICS MARKET BY APPLICATION: ABSOLUTE GROWTH
EXHIBIT 36 US DIGITAL THERAPEUTICS MARKET BY TREATMENT & DISEASE MANAGEMENT
EXHIBIT 37 US DIGITAL THERAPEUTICS MARKET BY TREATMENT & DISEASE MANAGEMENT: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 38 MAJOR VENDORS OFFERING DIGITAL THERAPEUTICS FOR TREATMENT & DISEASE MANAGEMENT
EXHIBIT 39 US TREATMENT & DISEASE MANAGEMENT DIGITAL THERAPEUTICS MARKET 2021-2027 ($ MILLION)
EXHIBIT 40 US DIGITAL THERAPEUTICS MARKET BY CHRONIC CARE: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 41 US CHRONIC CARE DIGITAL THERAPEUTICS MARKET 2021-2027 ($ MILLION)
EXHIBIT 42 US DIGITAL THERAPEUTICS MARKET BY MENTAL HEALTH & NEUROLOGICAL DISORDERS: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 43 US MENTAL HEALTH & NEUROLOGICAL DISORDER DIGITAL THERAPEUTICS MARKET 2021-2027 ($ MILLION)
EXHIBIT 44 US DIGITAL THERAPEUTICS MARKET BY OTHERS: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 45 US DIGITAL THERAPEUTICS MARKET BY OTHERS 2021-2027 ($ MILLION)
EXHIBIT 46 US PREVENTIVE CARE DIGITAL THERAPEUTICS MARKET
EXHIBIT 47 MAJOR VENDORS OFFERING DIGITAL THERAPEUTICS FOR PREVENTIVE CARE
EXHIBIT 48 US PREVENTIVE CARE DIGITAL THERAPEUTICS MARKET: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 49 US PREVENTIVE CARE DIGITAL THERAPEUTICS MARKET 2021-2027 ($ MILLION)
EXHIBIT 50 US DIGITAL THERAPEUTICS MARKET BY PRE-DIABETES: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 51 US PRE-DIABETES DIGITAL THERAPEUTICS MARKET 2021-2027 ($ MILLION)
EXHIBIT 52 US DIGITAL THERAPEUTICS MARKET BY WEIGHT MANAGEMENT: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 53 US WEIGHT MANAGEMENT DIGITAL THERAPEUTICS MARKET 2021-2027 ($ MILLION)
EXHIBIT 54 US DIGITAL THERAPEUTICS MARKET BY OTHERS: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 55 US DIGITAL THERAPEUTICS MARKET BY OTHERS 2021-2027 ($ MILLION)
EXHIBIT 56 INCREMENTAL GROWTH BY END-USER 2021 & 2027
EXHIBIT 57 US DIGITAL THERAPEUTICS MARKET BY END-USER
EXHIBIT 58 BENEFITS OF DIGITAL THERAPEUTICS TO KEY STAKEHOLDERS
EXHIBIT 59 US DIGITAL THERAPEUTICS MARKET BY END-USER: INCREMENTAL GROWTH
EXHIBIT 60 US DIGITAL THERAPEUTICS MARKET BY END-USER: ABSOLUTE GROWTH
EXHIBIT 61 US DIGITAL THERAPEUTICS MARKET BY HEALTHCARE PROVIDERS: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 62 US DIGITAL THERAPEUTICS MARKET BY HEALTHCARE PROVIDERS 2021-2027 ($ MILLION)
EXHIBIT 63 US DIGITAL THERAPEUTICS MARKET BY PATIENTS/INDIVIDUALS: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 64 US DIGITAL THERAPEUTICS MARKET BY PATIENTS/INDIVIDUALS 2021-2027 ($ MILLION)
EXHIBIT 65 US DIGITAL THERAPEUTICS MARKET BY PAYERS: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 66 US DIGITAL THERAPEUTICS MARKET BY PAYERS 2021-2027 ($ MILLION)
EXHIBIT 67 US DIGITAL THERAPEUTICS MARKET BY EMPLOYERS: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 68 US DIGITAL THERAPEUTICS MARKET BY EMPLOYERS 2021-2027 ($ MILLION)
EXHIBIT 69 US DIGITAL THERAPEUTICS MARKET BY OTHERS: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 70 US DIGITAL THERAPEUTICS MARKET BY OTHERS 2021-2027 ($ MILLION)
EXHIBIT 71 GROWTH STRATEGIES BY TOP DIGITAL THERAPEUTIC COMPANIES
EXHIBIT 72 PURE AND DIVERSIFIED PLAYERS IN THE US DIGITAL THERAPEUTICS MARKET
EXHIBIT 73 US DIGITAL THERAPEUTICS MARKET: MAJOR VENDOR'S STRENGTH & CAPABILITY ANALYSIS
EXHIBIT 74 POSITION OF MAJOR PLAYERS IN THE US DIGITAL THERAPEUTICS MARKET

LIST OF TABLES

TABLE 1 KEY CAVEATS
TABLE 2 CURRENCY CONVERSION 2015?2021
TABLE 3 US FDA APPROVED DIGITAL THERAPEUTICS (2010-2021)
TABLE 4 2MORROW: MAJOR PRODUCT OFFERINGS
TABLE 5 AKILI INTERACTIVE LABS: MAJOR PRODUCT OFFERINGS
TABLE 6 COGNOA: MAJOR PRODUCT OFFERINGS
TABLE 7 FITBIT: MAJOR PRODUCT OFFERINGS
TABLE 8 KAIA HEALTH: MAJOR PRODUCT OFFERINGS
TABLE 9 LARK TECHNOLOGIES: MAJOR PRODUCT OFFERINGS
TABLE 10 TELADOC HEALTH: MAJOR PRODUCT OFFERINGS
TABLE 11 OMADA HEALTH: MAJOR PRODUCT OFFERINGS
TABLE 12 PEAR THERAPEUTICS: MAJOR PRODUCT OFFERINGS
TABLE 13 RESMED: MAJOR PRODUCT OFFERINGS
TABLE 14 VOLUNTIS: MAJOR PRODUCT OFFERINGS
TABLE 15 WELLDOC: MAJOR PRODUCT OFFERINGS
TABLE 16 DARIO HEALTH: MAJOR PRODUCT OFFERINGS
TABLE 17 HAPPIFY HEALTH: MAJOR PRODUCT OFFERINGS
TABLE 18 ONE DROP: MAJOR PRODUCT OFFERINGS
TABLE 19 VIRTA HEALTH: MAJOR PRODUCT OFFERINGS
TABLE 20 AYOGO: MAJOR PRODUCT OFFERINGS
TABLE 21 BEHAVR: MAJOR PRODUCT OFFERINGS
TABLE 22 CALIBRATE HEALTH: MAJOR PRODUCT OFFERINGS
TABLE 23 CANARY HEALTH: MAJOR PRODUCT OFFERINGS
TABLE 24 CARA CARE: MAJOR PRODUCT OFFERINGS
TABLE 25 CARDIORENAL: MAJOR PRODUCT OFFERINGS
TABLE 26 CEREBRAL: MAJOR PRODUCT OFFERINGS
TABLE 27 COGNIFIT: MAJOR PRODUCT OFFERINGS
TABLE 28 CUREAPP: MAJOR PRODUCT OFFERINGS
TABLE 29 FREESPIRA: MAJOR PRODUCT OFFERINGS
TABLE 30 GINGER: MAJOR PRODUCT OFFERINGS
TABLE 31 GLOOKO: MAJOR PRODUCT OFFERINGS
TABLE 32 KELVI: MAJOR PRODUCT OFFERINGS
TABLE 33 MAHANA THERAPEUTICS: MAJOR PRODUCT OFFERINGS
TABLE 34 MANTRA HEALTH: MAJOR PRODUCT OFFERINGS
TABLE 35 MERU HEALTH: MAJOR PRODUCT OFFERINGS
TABLE 36 METAME HEALTH: MAJOR PRODUCT OFFERINGS
TABLE 37 MONUMENT: MAJOR PRODUCT OFFERINGS
TABLE 38 NEUROTRACK TECHNOLOGIES: MAJOR PRODUCT OFFERINGS
TABLE 39 NIGHTWARE: MAJOR PRODUCT OFFERINGS
TABLE 40 NOOM: MAJOR PRODUCT OFFERINGS
TABLE 41 SHARECARE: MAJOR PRODUCT OFFERINGS
TABLE 42 SWORD HEALTH: MAJOR PRODUCT OFFERINGS
TABLE 43 TALKSPACE: MAJOR PRODUCT OFFERINGS
TABLE 44 THIRTY MADISON: MAJOR PRODUCT OFFERINGS
TABLE 45 TRIPP: MAJOR PRODUCT OFFERINGS
TABLE 46 VIDA HEALTH: MAJOR PRODUCT OFFERINGS
TABLE 47 VIVANTE HEALTH: MAJOR PRODUCT OFFERINGS
TABLE 48 WORKIT HEALTH: MAJOR PRODUCT OFFERINGS
TABLE 49 US DIGITAL THERAPEUTICS MARKET BY APPLICATION 2021-2027 ($ MILLION)
TABLE 50 US DIGITAL THERAPEUTICS MARKET BY APPLICATION 2021-2027 (%)
TABLE 51 US DIGITAL THERAPEUTICS MARKET BY TREATMENT & DISEASE MANAGEMENT 2021-2027 ($ MILLION)
TABLE 52 US DIGITAL THERAPEUTICS MARKET BY TREATMENT & DISEASE MANAGEMENT 2021-2027 (%)
TABLE 53 US DIGITAL THERAPEUTICS MARKET BY PREVENTIVE CARE 2021-2027 ($ MILLION)
TABLE 54 US DIGITAL THERAPEUTICS MARKET BY PREVENTIVE CARE 2021-2027 (%)
TABLE 55 US DIGITAL THERAPEUTICS MARKET BY END-USER 2021-2027 ($ MILLION)
TABLE 56 US DIGITAL THERAPEUTICS MARKET BY END-USER 2021-2027 (%)

  • Not Sure / Need Reassuring
    • Confirm Content
      • Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:

        Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.

        Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.

        Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.

    • Sample Pages
      • With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.

        It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.

        To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.

    • Check for Alternatives
      • Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.

        To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.

  • Prices / Formats / Delivery
    • Prices
      • All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.

        Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.

    • Discounts
      • As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.

        Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.

        To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.

    • Available Currencies
      • Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.

        Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.

        To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.

    • Licenses
      • License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.

        If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.

    • Global Site License
      • The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.

        It is important to note that this may exclude Parent Companies or Subsidiaries.

        If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.

    • Formats
      • The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.

        If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.

    • Delivery
      • Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.

        Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.

        If a delay in delivery is expected you will be informed about it immediately.

    • Shipping Charges
      • As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.

        If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.

  • Ordering
    • By Credit Card
      • We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.

        Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.

        For more information on PayU please visit: https://www.payu.pl/en/about-us

    • By Money Transfer
      • If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.

        With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.

  • Security
    • Website security
      • We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.

        Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.

    • Credit Card Security
      • We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.

        PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.

PLEASE SELECT LICENSE